Rowena Callis
Papers
1
Total Citations
22
H-Index
1
About
Rowena Callis is a leading expert in high-throughput screening and assay development, with a primary focus on acoustic droplet ejection (ADE) technology and its application in cell-based assays. Her most significant contribution is pioneering the implementation and optimization of Labcyte Echo ADE systems for direct compound dosing into cell-based assays at AstraZeneca, a breakthrough that transformed the efficiency and accuracy of drug discovery workflows. Her seminal 2015 paper, "Implementation and Challenges of Direct Acoustic Dosing into Cell-Based Assays," which has garnered 22 citations, details the critical transition from traditional liquid handling to ADE, addressing key challenges such as cell viability, evaporation, and assay interference. This work established best practices that have been adopted globally across AstraZeneca's R&D sites since 2005, making ADE the preferred method for compound dosing. Callis's expertise has been instrumental in enabling miniaturized, high-throughput screening, reducing compound consumption and waste while improving data quality. Her contributions have had a lasting impact on the pharmaceutical industry, streamlining early-stage drug discovery and setting standards for acoustic dosing in cell-based systems.
Research Focus
Key Achievements
Top Papers
- 1